button bars forest bayes pooled summary circles
 
deaths (OS)

mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)

versus regorafenib
atezolizumab alone vs. regorafenib 1 889 [-470; 2248] /10000
65/90 vs. 57/90
atezolizumab plus cometinib vs. regorafenib 1 497 [-705; 1700] /10000
125/183 vs. 57/90

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons